AstraZeneca on Thursday released its fourth-quarter and full-year financial results, touting 6% total revenue growth for 2023 even as its COVID-19 business plummeted by more than 90%.
Featured Posts
Kyverna Therapeutics will debut on the Nasdaq Global Select Market under the ticker symbol KYTX after announcing that it is putting up for sale 14.5 million shares of its common stock for $22 apiece in an upsized initial public offering.
Krystal Biotech’s topical gene therapy Vyjuvek in an eyedrop formulation has restored the vision of a 13-year-old boy with the genetic condition dystrophic epidermolysis bullosa that scarred his eyes, according to a case brief published Thursday in The New England Journal of Medicine.
According to the announcement, the firm’s mission is to create and build companies developing innovative treatments that could “cure or transform the clinical management” of life-threatening diseases.
The new facility in Rockville, Maryland will focus on manufacturing for critical cancer trials and launch of its commercial cell therapy platforms.
The company’s three-drug combination met all primary and key secondary endpoints in two randomized controlled trials in cystic fibrosis patients, paving the way for an application to regulators.
Yesterday the company posted findings from an interim analysis of the Phase III DREAMM-7 trial showing that its antibody-drug conjugate Blenrep, when used in a three-drug regimen, led to a significant improvement in progression-free survival in patients with relapsed or refractory multiple myeloma.
The biotech is taking a synergistic approach to obesity with two muscle-preserving antibodies set to enter a Phase II study in mid-2024 in combination with existing incretin-based treatments.
The drug, nipocalimab, significantly reduced disease symptoms in a late-stage study with adult patients having myasthenia gravis, a chronic neuromuscular disorder that causes weakness in the voluntary muscle, the company announced.
Animal and early-stage human trial data for Amgen’s experimental obesity drug published in a medical journal showed that it promoted significant weight loss with an acceptable safety profile, the company said on Monday.